The purpose of this study was to compare transplantation outcomes in patients with hematologic malignancies who received marrow grafts from either phenotypically matched unrelated, one-antigen-mismatched unrelated, or highly human leukocyte antigen (HLA)-disparate family donors. Between 1993 and 2000, 139 patients underwent transplantation from unrelated donors (81 matched and 58 mismatched) an...

Transplant centers are turning to emotionally related or living unrelated kidney donors more often than in the past. Such donors are a benefit to the patient with end-stage renal disease, yet concern about their use persists. In the United States, the use of related donors has been well established in most centers. Nonetheless, there had been a reluctance to use nonrelatives that only recently ...

BACKGROUND Transplantation of bone marrow from unrelated donors is limited by a lack of HLA-matched donors and the risk of graft-versus-host disease (GVHD). Placental blood from sibling donors can reconstitute hematopoiesis. We report preliminary results of transplantation using partially HLA-mismatched placental blood from unrelated donors. METHODS Twenty-five consecutive patients, primarily...

Allogeneic haemopoietic stem cell transplantation has provided curative therapy for life-threatening malignant and non-malignant diseases in children for over 40 years. Only 25% of children in whom an allograft is indicated have the ideal option of a human leucocyte antigen-identical sibling donor. Substantial advances in the use of alternative donors (unrelated volunteer donors, haploidentical...

Hematopoietic stem cell transplantation (HSCT) is a medical procedure in the field of hematology and oncology, most often performed for patients with certain cancers of the blood or bone marrow. A lot of patients have no suitable HLA-matched donor within their family, so physicians must activate a "donor search process" by interacting with national and international donor registries who will se...

Transplantation of hematopoietic stem cells from human leukocyte antigen (HLA)-compatible unrelated volunteer donors have become feasible for more than 70% of patients without a family match. Chronic myeloid leukemia is the most common indication for unrelated donor marrow transplantation. The 5year survival for patients up the age of 50 years has improved to 75% with transplantation in the chr...